Rockcliffe Labs Inc. is a Canadian biotechnology venture creation platform that integrates academic research with clinical, regulatory, and commercialization expertise to bring therapies to market. The company develops a diversified pipeline of pharmaceuticals, diagnostics, and bio-based technologies by licensing breakthrough technologies from leading Canadian research institutions. Its lead program focuses on advancing a late-stage biomarker-based candidate for sepsis, aiming to address a significant unmet medical need in intensive care. Rockcliffe Labs holds exclusive rights in North America, with options for expansion into other global regions.